Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT07733765 |
| Consolidated Lead Sponsor | Pfizer |
| Therapeutic Condition Cohort | Immunology, Rheumatology, and Dermatology |
| Clinical Trial Phase | Phase III |
| Overall Recruitment Status | RECRUITING |
| Registered Enrollment | 336 participants (ESTIMATED) |
| Registered Start Date | 2026-07-30 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| California Dermatology & Clinical Research Institute | Encinitas, CA | Open Hospital Dossier -> |
| Dawes Fretzin Clinical Research Group, LLC | Indianapolis, IN | Open Hospital Dossier -> |
| University of Iowa | Iowa City, IA | Open Hospital Dossier -> |
| Johns Hopkins Hospital and Kimmel Cancer Center | Baltimore, MD | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.